Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 3 Next >
Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Shares by Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Present at the Bio International Convention
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Shares by Chairman
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Dosing of Additional Patients in Multiple Sclerosis Expanded Access Program
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Positive Results in Treating Spinal Cord Injury With Nasal Anti-CD3
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences not to engage in capital raising activities for the immediate future
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.